Emmanuel S. Antonarakis, MD - Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications - a podcast by PVI, PeerView Institute for Medical Education
from 2020-08-28T18:00
Go online to PeerView.com/JEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic. Upon completion of this activity, participants should be better able to: Describe the rationale for therapeutic targeting of DNA repair defects and the mechanism of PARP inhibition in managing BRCA-mutant prostate cancer, Review companion diagnostic tests that detect germline and somatic mutations within the DNA repair pathways, Discuss the latest evidence with PARP inhibitors in advanced prostate cancer harboring DNA repair defects, Identify patients with prostate cancer who may be candidates for clinical trial based therapeutic approaches, including studies testing combination regimens with PARP inhibitor components.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education